Topical delivery of fluconazole: In vitro skin penetration and permeation using emulsions as dosage forms

Drug Development and Industrial Pharmacy

Volumn 33, Issue 3, 2007, Pages 273-280

  Ayub, Alessandra C ^a   Gomes, Aline D M ^a   Lima, Marcus V C ^a   Vianna Soares, Cristina D ^a   Ferreira, Lucas A M ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Emulsions; Fluconazole; Formulations; Skin fungal infections; Skin permeation; Topical treatment and delivery

Indexed keywords

CARBOMER; CARBOMER 940; DIETHYLENE GLYCOL MONOETHYL ETHER; FLUCONAZOLE; LIQUID PARAFFIN; MYRISTIC ACID ISOPROPYL ESTER; POLYMER; POLYOXYETHYLENE 3 LAURYL ETHER; PROPYLENE GLYCOL; SODIUM HYDROXIDE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DERMATOPHYTE; DRUG DOSAGE FORM; DRUG DOSAGE FORM COMPARISON; DRUG PENETRATION; EAR; EMULSION; HAIRLESS MOUSE; IN VITRO STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; SKIN; SKIN PENETRATION; SWINE; TOPICAL TREATMENT;

ADMINISTRATION, TOPICAL; ANIMALS; ANTIFUNGAL AGENTS; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; EMULSIONS; FLUCONAZOLE; MALE; MICE; MYCOSES; SKIN ABSORPTION; SOLUBILITY; SWINE;

EID: 34247485817     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040600829989     Document Type: Article

References (26)

1. Alberti, I., Kalia, Y. N., Naik, A., Bonny, J., & Guy, R. H. (2001). Effect of ethanol and isopropyl myristate on the availability of topical terbinafine in human stratum corneum, in vivo. Int. J. Pharm., 219, 11-19.
2. Brenman, B., & Leyden, J. J. (1997). Overview of topical therapy for common superficial fungal infections and the role of new topical agents. J. Am. Acad. Dermatol., 36, 53-58.
3. Bronaugh, R. L., & Stewart, R. F. (1984). Methods for in vitro percutaneous absorption studies III: hydrophobic compounds. J. Pharm. Sci., 73, 1255-1258.
4. Degreef, H. J., & De-Doncker, P. R. G. (1994). Current therapy of dermatophytosis. J. Am. Acad. Dermatol., 31, S25-S30.
5. Dick, I. P., & Scott, R. C. (1992). Pig ear skin as an in vitro model for human skin permeability. J. Pharm. Pharmacol., 44, 640-645.
6. Diembeck, W., Beck, H., Benech-Kieffer, F., Courtellemont, P., Dupuis, J., Lovell, W., Paye, M., Spengler, J., & Steiling, W. (1999). Test guidelines for in vitro assessment of dermal absorption and percutaneous penetration of cosmetic ingredients. Food Chem. Toxicol., 37, 191-205.
7. Drake, L. A., Dinehart, S. M., Farmer, E. R., & Goltz, R. W. et al. (1996). Guidelines of care for superficial mycotic infections of the skin: tinea corporis, tinea curis, tinea faciei, tinea manuum and tinea pedis. J. Am. Acad. Dermatol., 34, 282-286.
8. Faergemann, J. (1999). Pharmacokinetics of fluconozole in skin and nails. J. Am. Acad. Dermatol., 40, S14-S20.
9. Faergemann, J., & Laufen, H. (1993). Levels of fluconazole in serum, stratum correum, epidemis-dermis (without stratum correum) and ecrine sweet. Clin. Exp. Dermatol., 18, 102-106.
10. Ferreira, L. A. M., Doucet, J., Seiller, M., Grossiord, J. L., Marty, J. P., & Wepierre, J. (1995). In vitro percutaneous absorption of metronidazole andglucose: comparison of w/o, w/o/w and w/o systems. Int. J. Pharm., 112, 169-179.
11. Klimke, K., & Schäfer-Korting, M. (1997). Effect of keratin on the efficacy of fluconozole. Mycoses, 40, 43-46.
12. Lesher, J. L. (1999). Oral therapy of common superficial fungal infections of the skin. J. Am. Acad. Dermatol., 40, S31-S34.
13. Mathy, F. X., Ntivunwa, D., Verbeeck, R. K., & Préat, V. (2005). Fluconazole distribution in rat dermis following intravenous and topical application: a microdialysis study. J. Pharm. Sci., 94, 770-780.
14. Moser, K., Kriwet, K., Naik, A., Kalia, Y. N., & Guy, R. H. (2001a). Passive skin penetration enhancement and its quantification in vitro. Eur. J. Pharm. Biopharm., 52, 103-112.
15. Moser, K., Kriwet, K., Kalia, Y. N., & Guy, R. H. (2001b). Enhanced skin permeation of a lipophilic drug using supersaturated formulations. J. Contr. Release, 73, 245-253.
16. Odom, R. B. (1994). Common superficial fungal infections in immunosupressed patients. J. Am. Acad. Dermatol., 31, S56-S59.
17. Odom, R. B. (1997). Update on topical therapy for superficial fungal infections: focus on butenafine. J. Am. Acad. Dermatol., 36, S1-S2.
18. Piérard, G. E., Arrese, J. E., & Piérard-Franchimont, C. (1996). Treatment and prophylaxis of tinea infections. Drugs, 52, 209-224.
19. Roy, S. D., Hou, S. -Y., Witham, S. L., & Glynn, G. L. (1994). Transdermal delivery of narcotic analgesics: comparative metabolism and permeability of human cadaver and hairless mouse skin. J. Pharm. Sci., 83, 1723-1728.
20. Simon, G. A., & Maibach, H. I. (2000). The pig as an experimental animal model of percutaneous permeation in man: qualitative and quantitative observations-an overview. Skin Pharmacol. Appl. Skin Physiol., 13, 229-234.
21. Surber, C., Wilhelm, K. P., & Maibach, H. I. (1991). In-vitro skin pharmacokinetics of acitretin: percutaneous absorption studies in intact and modified skin from three different species using different receptor solutions. J. Pharm. Pharmacol., 43, 836-840.
22. Touitou, E., Meidan, V. M., & Horwitz, E. (1998). Methods for quantitative determination of drug localized in the skin. J. Contr. Release, 56, 7-21.
23. Trottet, L., Merly, C., Mirza, M., Hadgraft, J., & Davis, A. F. (2004). Effect of finite doses of propylene glycol on enhancement of in vitro percutaneous permeation of loperamide hydrochloride. Int. J. Pharm., 274, 213-219.
24. Virgili, A., Zampino, M. R., & Mantovani, L. (2002). Fungal skin infections in organ transplant recipients. Am. J. Clin. Dermatol., 3, 19-35.
25. Wildfeuer, A., Faergemann, J., Laufen, H., Pfaff, G., Zimmermann, T., Seidl, H. P., & Lach, P. (1994). Bioavailability of fluconazole in the skin after oral medication. Mycoses, 37, 127-130.
26. William, A. C., & Barry, B. W. (1998). Chemical penetration enhancement: Possibilities and problems. In Dermal Absorption and Toxicity Assessment; Roberts, M. S., & Walters, K. A., Eds.; Marcel Dekker, Inc.: New York; 297-312.